Secretion of urokinase and metalloproteinase-9 induced by staurosporine is dependent on a tyrosine kinase pathway in mammary tumor cells

Int J Cancer. 1998 May 4;76(3):362-7. doi: 10.1002/(sici)1097-0215(19980504)76:3<362::aid-ijc13>3.0.co;2-d.

Abstract

Urokinase-type plasminogen activator (uPA) is a key serine protease involved in invasion and metastasis. We had shown that overproduction of uPA in tumor cells is controlled by a phospholipase D-protein kinase C-dependent pathway. Now we studied whether other signaling pathways participate in the regulation of constitutive uPA and metalloproteinase (MMP) overproduction in tumor cells. Staurosporine, a protein kinase inhibitor, stimulated uPA and MMP-9 secretion as measured by radial caseinolysis, zymography and Western blotting. Genistein, a specific tyrosine kinase inhibitor, reduced the constitutive and staurosporine-induced uPA and MMP-9 secretion. Interestingly, the phosphatase inhibitor vanadate stimulated uPA secretion. Verapamil, a calcium channel blocker, inhibited both endogenous and PMA-stimulated secretion of uPA but was unable to inhibit staurosporine-induced secretion. The alcohol n-butanol, a phospholipase D and protein kinase C inhibitor, besides inhibiting constitutive uPA secretion, blocked staurosporine-induced secretion. Our results suggest that constitutive and staurosporine-induced uPA and MMP-9 secretion by LM3 murine mammary tumor cells is controlled by an endogenous tyrosine kinase pathway and probably involves protein phosphatases. In addition, the staurosporine-induced signal regulating urokinase secretion is independent of extracellular calcium but dependent on phospholipase D.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Calcium / metabolism
  • Enzyme Inhibitors / pharmacology*
  • Female
  • Mammary Neoplasms, Animal / enzymology*
  • Metalloendopeptidases / drug effects*
  • Metalloendopeptidases / metabolism
  • Mice
  • Mice, Inbred BALB C
  • Plasminogen Activators / metabolism
  • Protein-Tyrosine Kinases / metabolism*
  • Staurosporine / pharmacology*
  • Tumor Cells, Cultured / drug effects
  • Urokinase-Type Plasminogen Activator / drug effects*
  • Urokinase-Type Plasminogen Activator / metabolism

Substances

  • Enzyme Inhibitors
  • Protein-Tyrosine Kinases
  • Plasminogen Activators
  • Urokinase-Type Plasminogen Activator
  • Metalloendopeptidases
  • Staurosporine
  • Calcium